Orphenadrine Levodopa

Bromocriptine is a dopamine agonist acting by direct stimulation of the dopamine receptors. In Parkinson s disease, it is reserved for use in patients who are intolerant to levodopa or in whom levodopa alone is not sufficient. Orphenadrine is an antimuscarinic indicated in Parkinson s disease. Antimuscarinics tend to be more effective than levodopa in targeting tremor rather than rigidity and bradykinesia. Moclobemide is an antidepressant referred to as a reversible monoamine oxidase inhibitor (RIAAA) type A. 

Co-careldopa is a combination of levodopa and the peripheral dopadecar-boxylase inhibitor. Co-careldopa is indicated in Parkinson s disease to improve bradykinesia and rigidity rather than tremor. Orphenadrine is an antimuscarinic agent indicated in patients with Parkinson s disease where tremor predominates. Trifluoperazine is a piperazine antipsychotic that should be used with caution in patients with Parkinson s disease as its use may exacerbate the condition. 

Simultaneous benztropine mesylate, biperiden, desipramine, hyosQramine, orphenadrine Noninterfering amantadine, carbidopa, levodopa... 

Examples Benztropine mesylate Orphenadrine citrate Chlorphenoxamine hydrochloride Levodopa and Amantadine hydrochloride. 

A study in 6 patients with Parkinson s disease taking levodopa plus car-hidopa or henserazide found that orphenadrine caused either a delay, a reduction, or an increase in levodopa absorption in 3 patients. Another... 

---